New treatments for inflammation in age-related macular degeneration
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
This study is working on a new injectable treatment for age-related macular degeneration (AMD) that uses tiny particles to help reduce inflammation and improve vision, making it easier for patients by cutting down on the number of injections they need.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10933407 on NIH RePORTER |
What this research studies
This research focuses on developing a new injectable treatment for age-related macular degeneration (AMD), a leading cause of blindness. The approach involves creating biodegradable nanoparticles that can release a therapeutic agent in response to inflammation caused by reactive oxygen species. By targeting the underlying inflammation and reducing the need for frequent injections, this study aims to improve patient outcomes and reduce treatment burden. The research will involve synthesizing and testing these nanoparticles to ensure they effectively deliver the therapeutic agent over an extended period.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage or atrophic age-related macular degeneration.
Not a fit: Patients with advanced wet age-related macular degeneration who are already receiving standard anti-VEGF treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less burdensome treatments for patients with age-related macular degeneration.
How similar studies have performed: Other research has shown promise in using nanoparticle delivery systems for therapeutics, suggesting potential success for this novel approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Swindle-Reilly, Katelyn E — Ohio State University
- Study coordinator: Swindle-Reilly, Katelyn E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.